Table 4.
Treatment of thymalfasin-treated and non-thymalfasin-treated groups
| SARS-CoV-2 nucleic acid negative conversion time (days) | SARS-CoV-2 IgG antibody level when SARS-CoV-2 nucleic acid turned negative | |
|---|---|---|
| Thymalfasin-treated group (n=24) | 18.42±5.06 | 64.52±53.38 |
| Non-thymalfasin-treated group (n=27) | 19.07±6.43 | 73.26±51.69 |
| t | 0.398 | 0.583 |
| P | 0.693 | 0.563 |